Medical affairs terminology is inconsistent between companies, between functions inside the same company, and sometimes between two people in the same meeting. These are twenty-four terms defined plainly, with a note wherever the same word carries different meanings for different teams.
Medical Affairs sits between clinical, commercial and regulatory, and it has absorbed vocabulary from all three. The result is a field where "insight" means one thing to a market researcher and another to a field medical team, and where two people can agree on a plan while meaning different things by half its words.
This glossary defines the terms as they are used in medical affairs measurement specifically. Where RocketMSL uses a term in a particular way, that is flagged rather than presented as the industry standard.
How to use this glossary
Terms are grouped by theme and listed alphabetically within each group. Where a definition depends on another term, that term is capitalised on first mention.
Entries marked (disputed) are terms where usage genuinely varies across the industry. If you are writing a measurement framework, these are the ones to define explicitly in your own documentation before anyone assumes.
People and roles
Field medical
The field-based portion of a Medical Affairs function — the teams who engage healthcare professionals in person or virtually, rather than working from a central office. Usually MSLs and their line management.
HCP (healthcare professional)
Any licensed clinician a medical affairs team engages: physicians, pharmacists, nurses, and allied health professionals. Broader than "physician" and preferred in most documentation because engagement is rarely limited to doctors.
KOL (key opinion leader) (disputed)
An HCP whose views influence the practice of others, through publications, guideline involvement, speaking or institutional standing. Disputed because the criteria are rarely written down, and because some organisations have moved away from the term in favour of describing the specific influence rather than assigning a label. Every KOL is an HCP; the reverse is not true.
Medical Affairs
The function within a pharmaceutical or biotechnology company responsible for scientific exchange with the healthcare community. Non-promotional by definition and structurally separated from commercial. Its remit typically covers field medical, medical information, evidence generation, and scientific communications.
MSL (Medical Science Liaison)
A field-based scientific role within Medical Affairs, responsible for peer-to-peer scientific exchange with HCPs. An MSL is not a sales role and in most jurisdictions is prohibited from promotional activity. The distinction is legal as well as cultural.
The scientific interaction
Ambient capture
Recording and structuring a conversation as it happens, rather than reconstructing it afterwards from memory. In a medical affairs context, ambient capture is consent-gated: where an HCP declines, the interaction is documented manually instead.
Communication topic
A defined scientific subject within a therapeutic area that a medical team plans to discuss — for example a mechanism of action, a safety profile, or a specific trial outcome. Communication topics are the level at which talking points and knowledge assessment usually operate.
Insight (disputed)
Something learned from an HCP that the organisation did not already know and can act on. Disputed because market research, commercial and medical teams all use the word for different things. In field medical, an insight is a specific observation from clinical practice — an unmet need, an evidence gap, a treatment barrier — not a general impression of how a meeting went. A record that says "positive discussion" is not an insight.
Scientific engagement
The overall practice of exchanging scientific information with HCPs. Distinct from promotional engagement in intent, content and governance. The unit of scientific engagement is a conversation, which is why measuring it has historically been difficult.
Talking point
A specific scientific point a medical team intends to raise with a given HCP, derived from approved content. RocketMSL refers to these as planned scientific talking points, and internally some teams call them KPIs — a usage worth avoiding in cross-functional settings, because everywhere else in the business a KPI is a performance indicator.
Therapeutic area
The disease or treatment domain a medical team covers — oncology, haematology, immunology and so on. Usually the primary unit of team organisation and of content approval.
Unmet need
A clinical problem for which existing options are inadequate, described from practice rather than inferred from data. One of the most valuable categories of insight, because it points at evidence that does not yet exist.
Measurement
Engagement quality (disputed)
Any attempt to describe how good a scientific interaction was, as opposed to whether it happened. Disputed because there is no industry-standard definition, and because many implementations measure the HCP's receptiveness rather than the substance of the discussion. Worth distinguishing from activity metrics, which count occurrences only.
HCP knowledge progression
The change in an HCP's scientific understanding of a product or communication topic over multiple interactions. Distinct from advocacy and from prescribing behaviour — an HCP can be highly informed and still, correctly, not prescribe.
Insight yield
A measure of what an HCP contributed during an interaction that the organisation did not previously know, assessed for substance rather than counted. A RocketMSL term. See what a depth measure should and should not include.
Scientific Discussion Depth
A measure of how much science moved during an interaction, composed of talking-point coverage and insight yield. A RocketMSL term, resolving to a score out of thirty. It deliberately excludes sentiment, the HCP's existing expertise, and any assessment of the MSL. Related to the broader question of how Medical Affairs measures its impact.
Segmentation
Grouping HCPs for planning purposes. Traditionally by commercial value or prescribing volume; increasingly, in medical contexts, by scientific understanding or engagement stage, which is a different and more defensible basis for a non-promotional function.
Talking-point coverage
The proportion of planned scientific talking points that were substantively discussed in an interaction. Distinguishes between discussed, mentioned in passing, and skipped. A RocketMSL term.
Compliance, safety and data
Adverse event (AE)
Any untoward medical occurrence in a patient administered a medicinal product, whether or not it is considered related to that product. If an AE is mentioned during a scientific interaction, it must be routed into the company's pharmacovigilance process within the timeframe its SOPs require — regardless of how it came up.
Medical information
The function that responds to unsolicited questions from HCPs about a product, usually including off-label questions that field teams cannot answer. Requests are logged, and responses are drawn from approved content.
MLR (medical, legal and regulatory review)
The internal approval process every piece of externally facing scientific material passes through. Material that has not cleared MLR cannot be used with HCPs, which is why approved content is the only defensible basis for a measurement benchmark.
Off-label enquiry
A question from an HCP about a use of a product outside its approved labelling. Field teams generally cannot respond directly; the enquiry is routed to Medical Information. The distinction between responding to an unsolicited question and promoting an unapproved use is legally significant.
Pharmacovigilance (PV)
The practice of detecting, assessing and preventing adverse effects of medicines. Relevant to scientific interactions because safety signals surface in conversation, and any system that captures those conversations has to route them rather than store them.
Recording consent
Explicit agreement from an HCP that a scientific interaction may be recorded. Captured per meeting rather than once per relationship. Where consent is declined, no audio is captured and documentation happens manually.
System of record
The authoritative source for a given category of data — usually a CRM for interaction logging. A system of intelligence sits on top of a system of record and adds analysis; it does not replace it. Confusing the two is a common cause of duplicate data entry.
Missing a term you would expect to see here? This glossary is maintained and expanded. Tell us what to add.
